Health Talk - World Health Organization Releases
It’s your favorite storyTelHER with your most discussed about segment..yes! Health Talk with an update on WHO Releases New Guidance on GLP-1 Weight Loss Drugs: What to Know.
The World Health Organization has issued new guidance on the use of popular GLP-1 drugs, like Ozempic, Wegovy, Mounjaro, and Zepbound, to address the “major global health challenge” of obesity.
A 2024 poll estimated that about 1 in 8 American adults had tried a GLP-1 drug, with the share of prescriptions continuing to rise. Did you try it?! I’ve not at all tell me your personal experience in the comments.
1. Use in Adults:
- GLP-1s can be used to treat adults with obesity, except for pregnant women.
- This recommendation is "conditional" due to limited data on long-term impacts, particularly regarding the effects of discontinuation.
2. Comprehensive Approach:
- GLP-1s are not a cure-all and should be used alongside intensive dietary and exercise changes.
- “Medicine alone will not solve the problem,” emphasized Dr. Francesca Celletti, WHO senior advisor for obesity.
Important Considerations:
- GLP-1 drugs are administered via weekly injections and work by targeting hormones that affect appetite, promoting feelings of fullness.
- Despite recent price cuts from manufacturers Novo Nordisk (Ozempic and Wegovy) and Eli Lilly (Mounjaro and Zepbound), a monthly dose can still cost hundreds of dollars.
- Users must ensure they get all necessary nutrients while reducing portion sizes, as these medications can lead to loss of muscle mass, highlighting the importance of exercise and strength training.
Societal Impact:
The WHO states that obesity is a problem requiring societal change. We must not neglect what we need to do in prevention," said Dr. Karen Sealey, director of the Healthy Caribbean Coalition and the Inter-American Heart Foundation.
#HealthNews #HealthTalk #BreakingNews #WorldHealthOrganization #WeightLossDrugs #ObesityDrugs
